Abstracts

Syphilis in HIV-Infected Mothers and Infants: Results From the NICHD/HPTN 040 Study

Background: The HIV and syphilis epidemics overlap, particularly in low and middle-income countries. Over 1 million pregnancies are complicated by congenital syphilis annually. Untreated maternal syphilis is associated with spontaneous abortion, stillbirth, prematurity, and neonatal and infant mortality. Methodology: We evaluated data available from 1664 mothers and 1684 infants enrolled in NICHD/HPTN 040 (P1043), a…

Predictors of Time to Switch to Second Line ART after First Line Failure in Johannesburg South Africa

Background: Many patients with documented virologic treatment failure on first line antiretroviral therapy (ART) need to be switched to a second line regimen. In South Africa, national treatment guidelines state that patients with two consecutive failing viral load measurements on non-nucleoside reverse transcriptase inhibitor first line treatment should be switched to a protease inhibitor based…

Favorable Long-term Outcomes of 2nd-Line ART Despite Drug-Resistant HIV-1 in Sub-Saharan Africa

Background: With the expansion of antiretroviral therapy (ART) in resource-limited settings, the number of people with treatment failure and need for 2nd-line regimens will increase. We assessed the long-term effectiveness of boosted protease inhibitor (bPI)-based 2nd-line ART in 13 African settings, in patients with and without extensive nucleoside reverse transcriptase inhibitor (NRTI) resistance mutations at…

Virologic Suppression With Second-Line Therapy: Does the Initial Regimen Matter?

Background: In those experiencing virologic failure (VF) on first-line antiretroviral therapy (ART), the impact of the initial drug regimen on the rate of subsequent virologic suppression (VS) is unknown. Methodology: We describe the outcomes of second-line therapy in those experiencing VF in the AIDS Clinical Trials Group A5202 trial, a randomized study comparing tenofovir/emtricitabine or…

Rosuvastatin Lowers Oxidative LDL in HIV-Infected Persons on Antiretroviral Therapy: SATURN-HIV

Background: Circulating oxidative low density lipoprotein (oxLDL), a known risk marker for cardiovascular disease (CVD), has not been well studied in HIV. Also, in HIV-uninfected populations, statins reduce oxLDL, but their effect in HIV is unknown. We report the first comprehensive study of oxLDL in HIV assessing its relationship to immune activation and CVD risk,…

After 52 Weeks Pitavastatin is Superior to Pravastatin for LDL-C Lowering in Patients with HIV

Background: Based on current guidelines for patients with HIV and dyslipidemia, statins with the lowest potential for drug-drug interactions (DDIs) with antiretroviral therapy (ART) are recommended. Pitavastatin (PTA) has a reduced potential for cytochrome P450-mediated DDIs and in the phase 4 trial INTREPID, PTA 4 mg demonstrated superior LDL-C reduction vs pravastatin (PRA) 40 mg…

Endothelial Progenitor Cells Increase in Older HIV-Infected Patients Receiving Telmisartan

Background: Bone marrow-derived endothelial progenitor cell (EPC) production reflects endothelial regenerative capacity. EPC production is partially mediated by angiotensin II, decreases with age, and correlates with measures of vascular function and cardiovascular disease (CVD; Hill, 2003; Schmidt- Lucke, 2010). Endothelial dysfunction and decreased EPC numbers have been documented in HIV-infected patients (Teofili 2010; da Silva…

Treatment of Pregnant and Breast-feeding Women: Evidence and Rationale for Option B+

Background: Option B+ initiation of lifelong antiretroviral therapy (ART) for all pregnant and breastfeeding women has generated great excitement and conjecture that it is the most promising approach to achieving global Elimination of Mother-to-Child-Transmission. As of January 2014 at least 20 countries had endorsed B+ for their national PMTCT programs and were actively implementing or…

No free rides: Consequences of fetal & infant ARV exposure among children remaining HIV-uninfected

Background: Implementation of World Health Organization guidelines for prevention of mother-to-child HIV transmission(MTCT)will result in increased in utero and breastfeeding antiretroviral (ARV)exposure among HIV-exposed uninfected (HEU) infants. In some regions of Africa more than 25% of all children will experience prolonged ARV exposure. Many studies have evaluated associations between in utero or direct infant exposure…